Opko Health Inc. (OPK) Receives Consensus Recommendation of “Hold” from Brokerages

Share on StockTwits

Shares of Opko Health Inc. (NASDAQ:OPK) have been given a consensus recommendation of “Hold” by the six research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.33.

A number of brokerages recently weighed in on OPK. ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, July 26th. BidaskClub upgraded Opko Health from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 24th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $20.00 price objective on shares of Opko Health in a research report on Tuesday, August 7th.

OPK traded down $0.08 during trading on Friday, reaching $3.59. The company had a trading volume of 3,255,649 shares, compared to its average volume of 5,073,589. Opko Health has a 12-month low of $2.66 and a 12-month high of $6.99. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.06. The firm had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. On average, equities research analysts anticipate that Opko Health will post -0.23 earnings per share for the current year.

In other Opko Health news, CEO Phillip Md Et Al Frost acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, August 28th. The stock was purchased at an average cost of $5.80 per share, for a total transaction of $29,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $17,799,915.80. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired a total of 225,000 shares of company stock valued at $1,210,850 over the last 90 days. Corporate insiders own 42.74% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the business. ING Groep NV acquired a new stake in Opko Health during the 2nd quarter worth about $1,575,000. BlackRock Inc. lifted its holdings in shares of Opko Health by 38.7% during the 2nd quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock valued at $138,798,000 after buying an additional 8,237,434 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Opko Health by 842.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 106,050 shares of the biotechnology company’s stock valued at $498,000 after buying an additional 94,799 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Opko Health by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock valued at $1,585,000 after buying an additional 19,316 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Opko Health by 4.0% during the 1st quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock valued at $5,549,000 after buying an additional 66,562 shares during the last quarter. Hedge funds and other institutional investors own 24.70% of the company’s stock.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Further Reading: Hedge Funds – How They Work For Investors

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply